Pulmonary fibrosis and the TGF-β signaling axis: Advances in targeted therapeutics

Area of Science:

• Pulmonary Medicine
• Cellular Biology
• Pharmacology

Background:

• Pulmonary fibrosis (PF) is a progressive lung disease with limited treatment options.
• The transforming growth factor-β (TGF-β) signaling pathway is crucial in fibrosis development.
• Identifying effective therapeutic targets for PF is a significant unmet need.

Purpose of the Study:

• To review the current understanding of the TGF-β/Smad axis in pulmonary fibrosis.
• To explore interconnected signaling pathways (PI3K/Akt, MAPK, Wnt, Rho-GTPase) involved in PF.
• To summarize recent therapeutic strategies targeting these fibrotic pathways.

Main Methods:

• Comprehensive literature review of the TGF-β/Smad axis and related pathways in PF.
• Analysis of molecular mechanisms underlying fibrosis.
• Summary of therapeutic interventions including small-molecule inhibitors, biologics, and combination regimens.

Main Results:

• The TGF-β/Smad axis plays a central role in the molecular pathogenesis of PF.
• Interconnected pathways like PI3K/Akt, MAPK, Wnt, and Rho-GTPase significantly influence fibrotic processes.
• Various therapeutic agents targeting these pathways have been investigated recently.

Conclusions:

• The TGF-β/Smad pathway and its associated networks are critical targets for PF treatment.
• Further research into these pathways may reveal novel therapeutic avenues.
• Understanding these molecular networks is essential for developing effective anti-fibrotic therapies.